title: Production of therapeutic antibodies with controlled fucosylation.
abstract: The clinical success of therapeutic antibodies is demonstrated by the number of antibody therapeutics that have been brought to market and the increasing number of therapeutic antibodies in development. Recombinant antibodies are molecular-targeted therapeutic agents and represent a major new class of drugs. However, it is still very important to optimize and maximize the clinical efficacy of therapeutic antibodies, in part to help lower the cost of therapeutic antibodies by potentially reducing the dose or the duration of treatment. Clinical trials using therapeutic antibodies fully lacking core fucose residue in the Fc oligosaccharides are currently underway, and their remarkable physiological activities in humans in vivo have attracted attention as next-generation therapeutic antibody approaches with improved efficacy. Thus, an industrially applicable antibody production process that provides consistent yields of fully non-fucosylated antibody therapeutics with fixed quality has become a key goal in the successful development of next-generation therapeutic agents. In this article, we review the current technologies for production of therapeutic antibodies with control of fucosylation of the Fc N-glycans.
authors.affiliation: Antibody Research Laboratories, Research Division, Kyowa Hakko Kirin Co., Ltd., Machida-shi, Tokyo, Japan.
authors.forename: Naoko
authors.initials: N
authors.lastname: Yamane-Ohnuki
authors.forename: Mitsuo
authors.initials: M
authors.lastname: Satoh
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000235:genetics / Q000378:metabolism / Q000627:therapeutic use*; D000920:Antibody-Dependent Cell Cytotoxicity / Q000187:drug effects / Q000235:genetics; D001709:Biotechnology; D015195:Drug Design; D005643:Fucose / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D007127:Immunoglobulin Constant Regions / Q000737:chemistry / Q000378:metabolism; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology; D011485:Protein Binding / Q000187:drug effects / Q000235:genetics; D015202:Protein Engineering; D011994:Recombinant Proteins / Q000235:genetics / Q000378:metabolism / Q000627:therapeutic use*
chemical_list: D000911:Antibodies, Monoclonal; D007127:Immunoglobulin Constant Regions; D011994:Recombinant Proteins; D005643:Fucose